Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

News

News
Adjuvant Osimertinib Significantly Improved Overall Survival Among Patients With EGFR-Mutated NSCLC
07/10/2023
According to final analysis results from the phase 3 ADAURA trial, adjuvant osimertinib significantly improved overall survival among patients with completely resected EGFR-mutated, stage 1B-2A NSCLC.
According to final analysis results from the phase 3 ADAURA trial, adjuvant osimertinib significantly improved overall survival among patients with completely resected EGFR-mutated, stage 1B-2A NSCLC.
According to final analysis...
07/10/2023
Oncology
Roy Herbst, MD, PhD, Yale Cancer Center
Videos
Adjuvant Osimertinib Improved Overall Survival for Patients With EGFR-Mutant NSCLC
06/19/2023
At the 2023 ASCO Annual Meeting, Roy Herbst, MD, PhD, shared results from the overall survival analysis of the phase 3 ADAURA trial, evaluating adjuvant osimertinib for patients with resected EGFR-mutated non-small cell lung cancer.
At the 2023 ASCO Annual Meeting, Roy Herbst, MD, PhD, shared results from the overall survival analysis of the phase 3 ADAURA trial, evaluating adjuvant osimertinib for patients with resected EGFR-mutated non-small cell lung cancer.
At the 2023 ASCO Annual Meeting,...
06/19/2023
Oncology
News
Concurrent Osimertinib and Chemotherapy for First-line EGFR-Mutated NSCLC
05/25/2023
A phase 2 trial confirmed the safety and efficacy of concurrent osimertinib and platinum-based chemotherapy in patients with previously untreated EGFR-mutated non-small cell lung cancer.
A phase 2 trial confirmed the safety and efficacy of concurrent osimertinib and platinum-based chemotherapy in patients with previously untreated EGFR-mutated non-small cell lung cancer.
A phase 2 trial confirmed the...
05/25/2023
Oncology

Advertisement

News
Concurrent Osimertinib and Chemotherapy for First-line EGFR-Mutated NSCLC
05/25/2023
A phase 2 trial confirmed the safety and efficacy of concurrent osimertinib and platinum-based chemotherapy in patients with previously untreated EGFR-mutated non-small cell lung cancer.
A phase 2 trial confirmed the safety and efficacy of concurrent osimertinib and platinum-based chemotherapy in patients with previously untreated EGFR-mutated non-small cell lung cancer.
A phase 2 trial confirmed the...
05/25/2023
Oncology
News
Osimertinib for Patients With Progressive EGFR-Mutated T790M-Negative NSCLC
04/21/2023
Osimertinib demonstrated modest antitumor activity in patients with EGFR-mutated T790M-negative non-small cell lung cancer that has progressed after treatment, according to a phase 2 study.
Osimertinib demonstrated modest antitumor activity in patients with EGFR-mutated T790M-negative non-small cell lung cancer that has progressed after treatment, according to a phase 2 study.
Osimertinib demonstrated modest...
04/21/2023
Oncology
News
Osimertinib for Patients With Progressive EGFR-Mutated T790M-Negative NSCLC
04/21/2023
Osimertinib demonstrated modest antitumor activity in patients with EGFR-mutated T790M-negative non-small cell lung cancer that has progressed after treatment, according to a phase 2 study.
Osimertinib demonstrated modest antitumor activity in patients with EGFR-mutated T790M-negative non-small cell lung cancer that has progressed after treatment, according to a phase 2 study.
Osimertinib demonstrated modest...
04/21/2023
Oncology

Advertisement

News
EGFR Mutation Prevalence in Non-Small Cell Lung Cancer in West-European Patient Population
03/09/2023
The prevalence of EGFR mutations in West-European patients with non-small cell lung cancer were found to be statistically substantial.
The prevalence of EGFR mutations in West-European patients with non-small cell lung cancer were found to be statistically substantial.
The prevalence of EGFR mutations...
03/09/2023
Oncology
News
EGFR Mutation Prevalence in Non-Small Cell Lung Cancer in West-European Patient Population
03/09/2023
The prevalence of EGFR mutations in West-European patients with non-small cell lung cancer were found to be statistically substantial.
The prevalence of EGFR mutations in West-European patients with non-small cell lung cancer were found to be statistically substantial.
The prevalence of EGFR mutations...
03/09/2023
Oncology
News
PD-L1 Score Demonstrates Value as Prognostic Biomarker in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer
01/18/2023
Study finds PD-L1 scores exhibit value in predicting survival rates in patients with early stage EFGR-mutated non-small cell lung cancer.
Study finds PD-L1 scores exhibit value in predicting survival rates in patients with early stage EFGR-mutated non-small cell lung cancer.
Study finds PD-L1 scores exhibit...
01/18/2023
Oncology

Advertisement

News
Somatic Missense Mutations Identified as Promising Targets of Future Treatment for NSCLC
08/29/2022
Study findings reveal 4 somatic missense mutations as rare genetic markers for NSCLC, making them promising targets for study and development of future treatments.
Study findings reveal 4 somatic missense mutations as rare genetic markers for NSCLC, making them promising targets for study and development of future treatments.
Study findings reveal 4 somatic...
08/29/2022
Oncology

Advertisement

Advertisement

Advertisement

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use